National Cancer Institute
Doctor using a smartphone Photo by Daniel Sone,
Novo Nordisk has launched a web-based portal that allows hemophilia patients to share real-time data on their treatment and bleeding events with their healthcare providers.
The portal, HemaGo™ XChange, is an extension of Novo Nordisk’s HemaGo™ mobile application and website, which were launched in 2012.
Data a patient enters into the HemaGo™ diary can be shared through the HemaGo™ XChange with the patient’s hemophilia treatment network.
Patients may also choose to have these data entered into the American Thrombosis and Hemostasis Network’s (ATHN) national database of bleeding disorder treatment information.
“We developed HemaGo™ XChange to help drive progress in hemophilia management by turning static data into usable information for people with hemophilia, their care teams, and even researchers,” said John Spera, vice-president of biopharmaceuticals marketing at Novo Nordisk Inc.
“With timely information about the daily experiences of patients, including bleeds, healthcare providers can adjust their care to better fit patient lives.”
Patients using HemaGo™ can:
- Provide information to their healthcare team, including access to treatment and bleed data, in real time through the HemaGo™ XChange web portal
- Choose to email data directly from the app or website at any time
- Opt-in through their hemophilia treatment center to have their data integrated into ATHN’s national database of bleeding disorder treatment information. ATHN will use and share these data with hemophilia treatment centers to foster its mission of advancing knowledge and transforming care for the bleeding and clotting disorders community.
Providers invited by patients to connect via the HemaGo™ XChange portal can:
- View details about treatments, bleeds, and more for multiple patients
- Track when and how much factor is used; the type of infusion, vial, and dosing amounts; and information about any other medications
- View data on the type, location, duration, frequency, and status of bleeds
- View patient and caregiver life experiences, such as pain and health scores or how a bleeding disorder has affected work, school, or other activities
- Download in-depth reports for all recorded information.
Novo Nordisk does not have access to patient-specific information. The company’s access is restricted to de-identified data in which the individual sources of the data cannot be identified, in accordance with Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security Rules.
To download the HemaGo™ app or join the HemaGo™ XChange, visit www.HemaGo.com and www.HGXchange.com. The HemaGo™ app is available for iPhone and Android phones.
